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ABSTRACT OF THESIS

PHARMACIST PROVISION OF CONTRACEPTION SERVICES IN KENTUCKY:
OPINIONS AND POLICY INTERVENTIONS
Unintended pregnancy continues to be a prevalent issue across the United States,
impacting millions of women annually. While several states have enacted policies
expanding pharmacist services to allow for provision of hormonal contraception, Kentucky
has yet to do so. Likewise, although provision of nonprescription hormonal contraception
could be authorized under Kentucky regulation, prior to this study, this had yet to be done.
The objectives of this study were to 1) understand the opinions of Kentucky pharmacists
and student pharmacists regarding provision of hormonal contraception services through a
board-authorized protocol, 2) understand the opinions of Kentucky pharmacists and
student pharmacists regarding provision of nonprescription emergency contraception
services through a board-authorized protocol, and 3) identify and implement policy-based
solutions to increase access to nonprescription emergency contraception.
Two questionnaires, both approved by the University of Kentucky Institutional
Review Board (IRB) were developed via REDCap with questions pertaining to pharmacists
and student pharmacists, respectively. The pharmacist questionnaire was disseminated via
email or private Facebook group post to a convenience sample of Kentucky pharmacists.
The student pharmacist questionnaire was disseminated via Canvas to first through third
professional year (PY1-PY3) students at the University of Kentucky College of Pharmacy.
Surveys were analyzed using descriptive statistics. A multivariable logistic regression
model was used for both surveys to identify any significant differences in odds of support
for provision of hormonal contraception across various demographic factors. Additionally,
McNemar’s test was used for both surveys to identify any significant differences in support
between dosage forms. A protocol for provision of emergency contraception was created
and presented for approval to the Kentucky Board of Pharmacy. Development of a training
program was initiated and plans for future implementation strategies were begun.
Pharmacists were found to be generally supportive of provision of hormonal
contraception, with support being highest for oral (61%) and transdermal (54%) dosage
forms. While lower, support was existent for provision of injectable (38%) and vaginal
(47%) dosage forms as well. Students, however, were largely supportive of oral (91%),
transdermal (82%), vaginal (73%), and injectable (66%) dosage forms. Support regarding
provision of emergency contraception via board-authorized protocol was high for both
pharmacists (65%) and student pharmacists (88%). Multivariable logistic regression
analyses showed that pharmacists in practice 11-30 years were found to be at significantly

decreased odds of support for oral, transdermal, and vaginal dosage forms compared to
those in practice 10 years or less. With regard to the student survey, PY3 students were
found to be at higher odds of support for provision of the oral and vaginal dosage forms.
Additionally, students who anticipate practicing in a hospital inpatient setting were at
higher odds of support for provision of the injectable dosage form. A protocol for provision
of nonprescription emergency contraception was approved by the Kentucky Board of
Pharmacy and training program development remains underway.
This work provides the framework for pharmacists to provide nonprescription
emergency contraception via protocol. Additionally, data collected regarding pharmacist
and student pharmacist opinions provide the foundation for discussion regarding
pharmacist provision of hormonal contraception in Kentucky.
KEYWORDS: Pharmacist Opinions, Student Pharmacist Opinions, Contraception,
Pharmacist Services
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CHAPTER 1. BACKGROUND
1.1

Unintended Pregnancy
1.1.1

Overview and Prevalence

Since the late 20th century, unintended pregnancy has evolved into a significant
public health concern in the United States and other countries. A 2016 study analyzing data
from 2008-2011 found that 45% of pregnancies in the United States were unintended.1
Although this represented a decrease from the 51% of pregnancies in 2008, rates of
unintended pregnancy in those below the poverty line or cohabitating remained two to three
times the national average.1 While progress has been made in reducing unintended
pregnancies, much remains to be done to combat the 2.8 million unintended pregnancies
that occur yearly. A study analyzing risk factors associated with greater incidence of
multiple unintended pregnancies found that increased age, race (African American or
Hispanic), non-voluntary first intercourse, sex trade involvement, and previous abortion all
significantly increased risk.2 The same study found that use of combination hormonal
contraceptives significantly decreased the risk for unintended pregnancies, outlining the
importance of expanding access to hormonal contraception.
1.1.2

Costs of Unintended Pregnancy

With large numbers of unintended pregnancies occurring annually, particularly in
medically underserved populations and in those below the poverty line, the associated costs
are numerous. Utilizing data collected in 2006 from the Pregnancy Risk Assessment
Monitoring System, a study analyzing the public monetary burden of unintended
pregnancies found that government expenditures nationwide (including both federal and
1

state) totaled $11.1 billion.3 In Kentucky alone, government expenditures on unintended
pregnancies totaled $248.3 million. This substantial number is due to the fact that 64% of
births resulting from unintended pregnancies were publicly funded, placing a large portion
of the monetary burden upon state government. It is estimated that prevention of
unintended pregnancies could reap government and taxpayer savings as high as $6.2
billion.4 While prevention does not come without its associated costs, estimates based on
previous expenditures point to a savings of $3-6 for every dollar spent to provide publiclyfunded contraceptive services.5-6
1.1.3

Barriers to Contraception Access

While aforementioned studies have shown that use of hormonal contraceptives
greatly decreases the risk of multiple unintended pregnancies2, access to hormonal
contraceptives can be a limiting factor in the prevention of such pregnancies. Nearly half
of unintended pregnancies occur in women who are sexually active and who are not using
contraception.7 In a recent survey of women at risk for pregnancy, reported barriers
included problems attaining a prescription or getting refills (29%), cost barriers or lack of
insurance (14%), challenges obtaining an appointment or getting to a clinic (13%),
clinician requirement of a pelvic exam or pap smear (13%), having no regular
physician/clinic (10%), and difficulty accessing a pharmacy (4%).8 With pharmacy being
the least cited barrier, pharmacist-provision of hormonal contraception provides
opportunity to bypass the most common barriers associated with attaining hormonal
contraception and provide care to those who would otherwise be at risk for unintended
pregnancy.
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1.2

Pharmacist-Initiated Hormonal Contraception
1.2.1

Current Legislative Landscape

Pharmacist scope of practice is determined at a state level rather than federally. This
being the case, legislative action must take place in individual states prior to expansion of
pharmacist services. After scope is provided legislatively, administrative regulations
through the state Board of Pharmacy delineate how scope is applied and implemented.
In recent years, scope of practice expansion authorizing pharmacists to directly
provide prescription hormonal contraception has gained traction. In 2016, Oregon became
the first state to fully implement direct pharmacist provision of hormonal contraception,
with California quickly following suit. Currently, at least 12 states have authorized
pharmacists to directly provide prescription hormonal contraception, either through a
collaborative practice agreement, statewide protocol, or standing order.9 An additional 4
states, plus Washington D.C., have statewide standing orders or protocols currently in
process, but not yet fully implemented.9 Bipartisan support has been a crucial factor for the
recent advancements made in the field, with more than half of the currently proposed
legislation being Republican-sponsored while earlier legislation was primarily sponsored
by the Democratic Party.9 States have varying age requirements and permitted dosage
forms, with some being fairly restrictive and some having nearly no restrictions. New
Mexico, having one of the most progressive laws, allows for prescription of the oral,
transdermal, vaginal, injectable, and nonhormonal methods to any age patient.10 Colorado,
on the other hand, allows for only pill and patch to be prescribed to patients 18 and older.11
As evidenced by the growing number of states implementing legislation and the variation
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lying within, a key component of pharmacist-initiated contraception is the tailoring of
restrictions to meet the values and comfort level of the population served as well as the
pharmacists providing the service.
Table 1-1 Summary of Policies Currently Implemented
State
Year
Dosage Form(s)
Available
Oregon
2016
Oral, Transdermal, Vaginal, Injectable

Age
Requirements
None

California

2016

Oral, Transdermal, Vaginal, Injectable

None

Colorado

2017

Oral, Transdermal

18+

Hawaii

2018

Oral, Transdermal, Vaginal

None

New
Mexico
Maryland

2018

None

2019

Oral, Transdermal, Vaginal, Injectable,
Nonhormonal Methods
Oral, Transdermal, Vaginal, Injectable

Utah

2019

Oral, Transdermal, Vaginal

18+

Minnesota

2020

Oral, Transdermal, Vaginal

Virginia

2021

Oral, Transdermal, Vaginal, Injectable

18+ (unless
prior use)
18+

None

Others Offering via Collaborative Practice Agreement: Washington, Idaho,
Montana, Michigan, Tennessee, Nebraska, South Dakota, Wisconsin
Others with Statewide Protocols or Standing Orders in Progress: Arkansas, New
Hampshire, Vermont, West Virginia, Washington D.C.
Adapted from: The Birth Control Pharmacist9
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Figure 1-1: Map of Current Policies9 (created using Mapchart)
1.2.2

Opinions on Pharmacist-Initiated Contraception
1.2.2.1 Provider Opinions

A key concern of many in favor of pharmacist-initiated hormonal contraception is
resistance from physicians and advanced-practice clinicians (defined as providers by the
Social Security Act)12. A 2016 survey of physician and advanced-practice clinician
opinions, however, found that 76% of physicians and 70% of midlevel providers were in
favor of expanded access to hormonal contraception through pharmacist provision.13
Although many were found to be supportive, many remained concerned that pharmacistinitiated contraception may decrease reproductive health preventive screening. Other
research has also concluded that these providers are supportive of pharmacist-initiated
contraception,14 illustrating the evolving support of pharmacists as healthcare providers.
1.2.2.2 Pharmacist Opinions
5

In 2009, prior to the initial surge in state legislation authorizing pharmacist
provision of hormonal contraception, studies aiming to gauge pharmacist opinions on the
subject emerged. The first of such, a nationwide descriptive study, found that 85% of
pharmacists surveyed were interested in providing direct access to hormonal
contraception.15 An Oregon study, conducted prior to implementation of their current
authority, found that, with proper training and reimbursements, 57% of pharmacists were
interested in the provision of various contraceptive methods.16 They also found that
pharmacists were more likely to be interested in provision if they lived in urban areas or
currently offered OTC emergency contraception access. An Ohio study conducted in 2017
found that, of the pharmacists surveyed, 57% agreed that oral and transdermal hormonal
contraceptive methods should be available through a collaborative practice agreement or
statewide protocol.17 More recently, when surveyed regarding their support for provision
of hormonal contraception, 83% of North Carolina community pharmacists were
supportive.18 Studies conducted regarding pharmacists’ knowledge/comfort level have
concluded that, given additional training, the majority of pharmacists feel comfortable with
their ability to screen for contraindications and/or to provide hormonal contraception.15,19,20
1.2.2.3 Student Pharmacist Opinions
Given the growing foundation of knowledge provided to those in training to
become pharmacists, studies have become available gauging students’ opinions on the
provision of hormonal contraception. One such study, conducted in California in 2007,
found that 96.2% of students were interested in provision of hormonal contraceptive
services.21 Limited research has been published regarding student opinions on the provision
of hormonal contraception services since this time. This wide interest level did, however,
6

illustrate the shift in pharmacy in recent years to provision of clinical services and, in part,
explains the growing sentiment in the field for advancement of the profession through
provision of hormonal contraception services.
1.2.2.4 Patient Opinions
Given support shown by both providers and those within the profession of
pharmacy, a crucial step in understanding the feasibility of pharmacist-initiated hormonal
contraception lies within understanding the opinions of the women who would seek to
obtain contraceptive services. A 2006 study found that, of the women surveyed, 68% of
women said that they would use pharmacy access to hormonal contraception.22 In addition,
they found that interest was higher in low-income and uninsured women, two key
demographic groups in reducing the incidence and societal burden of unintended
pregnancy. A more recent study focusing on older teens’ (ages 18-19) attitudes toward
pharmacy access to hormonal contraception found that nearly all of the participants were
supportive of pharmacy access and also believed that the increase in access would lead to
both personal and societal benefits.23
1.2.3

Consideration of Potential Barriers

Provision of hormonal contraception by pharmacists is not, however, without it
concerns. Perceived barriers have been expressed by many members of the community,
including pharmacists, providers, and potential patients. Common concerns include
decreased reproductive health screening, inadequate pharmacist time, liability concerns,
reimbursement, the need for additional training, and belief that pelvic examination is
necessary prior to provision.13,15,16,21 With regard to time concerns, a recent study
7

conducted in Oregon found that the average pharmacist time to perform the service was
7.8 minutes, without accounting for documentation and dispensing of the product.24 The
study concluded that the time impact of pharmacist provision of hormonal contraception
was similar to that of immunizations and point-of-care testing. While the belief that pelvic
examinations are necessary prior to receiving hormonal contraception is common among
both providers and pharmacists, many studies have refuted this idea25–27 and, in reviewing
the evidence associated with pelvic examinations, the American College of Obstetrics and
Gynecology has stated that screening for cervical cancer or STIs is not medically required
for provision of hormonal contraception.28 While these concerns could be alleviated with
proper education on current literature and opinions, other barriers mentioned (e.g.,
reimbursement, the need for additional training) need to be addressed in the future to
further increase interest in pharmacist-provision of hormonal contraception. Currently, the
National Community Pharmacists Association (NCPA) is working to address training
concerns by offering an online course to provide training on provision of hormonal
contraception in certain states where such services are available.29 As for reimbursement,
California has addressed this issue through their state Medicaid program (Medi-Cal) which,
as of April 2019, offers reimbursement to pharmacists for services provided, including the
provision of hormonal contraception.30 Other states, such as Washington and Tennessee,
have addressed concerns by mandating managed health insurance issuers reimburse
pharmacists for services provided within their scope of practice.31 While the effect of
reimbursement in increasing uptake and availability of pharmacist-provided hormonal
contraception is yet to be quantified, these steps are necessary in alleviating the barriers
associated with provision of such services.
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1.2.4

Outcomes of Pharmacist-Initiated Hormonal Contraception
1.2.4.1 Implementation

One key factor in the effectiveness of pharmacist-initiated hormonal contraception
in fighting the unintended pregnancy epidemic lies with the prevalence of implementation
across pharmacies in supportive states. A 2018 Oregon study seeking to analyze the change
in pharmacists’ motivation to prescribe hormonal contraception over the course of the first
12 months of experience found that pharmacist prescribing of hormonal contraception
increased and was continuing to increase at the 12-month mark.32 A more recent study
analyzing the prevalence of pharmacist-prescribed oral or transdermal contraception in the
Oregon Medicaid population found that, of new prescriptions, 10% were obtained from a
pharmacist.33 They also found that over 70% of prescriptions issued by pharmacists were
for patients with no history of hormonal contraceptive use within the preceding 30 days,
illustrating the impact that pharmacist-prescribed contraception has had on the at-risk
Medicaid population. While not all pharmacies in states with authorizing legislation offer
contraceptive services, a recent California survey found that only 12.3% of responding
pharmacists indicated that they would not offer the service in the future.34 Currently, there
are currently over 1100 pharmacies in the United States offering pharmacist-initiated
hormonal contraception9. Collectively, research done since implementation has provided
evidence that, not only can pharmacies be an access point, but, given the opportunity,
pharmacists are willing to provide the service.
1.2.4.2 Impact

9

Given the aforementioned predicted savings and the increasing prevalence of
implementation, the question remains as to whether these savings have come into fruition.
A recent study aimed to analyze the monetary impact implementation has had on the
Oregon Medicaid population.35 Utilizing a decision-analytic model, they found that the
policy expanding the scope of pharmacists to prescribe hormonal contraception had averted
an estimated 51 unintended pregnancies resulting in a savings of $1.6 million dollars over
the course of the first 24 months. The study also aimed to determine the impact on quality
of life, finding that 158 QALYs were gained per 198,000 women and concluding that the
decision to expand scope of practice had, in fact, improved quality of life. In addition to
this, other research done on the subject has also found that nearly all women receiving
contraception services from a pharmacist are very satisfied with their experience.36,37 With
growing implementation in permitting states and the quantifiable impact seen both
monetarily and in satisfaction and quality of life, ample evidence is present supporting the
idea that pharmacists can effectively aid in stemming the tide of unintended pregnancies
through direct provision of hormonal contraception.

1.3

Pharmacist-Initiated Emergency Contraception
1.3.1

Overview of Emergency Contraception

Emergency contraception has long been a crucial component in prevention of
unintended pregnancy. Currently, other than the Yuzpe method, three forms of emergency
contraception exist: levonorgestrel, ulipristal acetate, and intrauterine devices (IUDs).38
While most effective during the first 24 hours, they remain effective up to 120 hours,
depending on the type.39 Due to the importance of timely initiation of emergency
10

contraception, effort was made during the early 2000’s to advocate for nonprescription
(commonly known as over-the-counter or OTC) availability of emergency contraception.
In 2013, a single-dose regimen of levonorgestrel became available OTC in the United
States with no age requirements.38 While this significantly increased access to emergency
contraception, barriers remained that continue to hinder usage and availability. According
to the Guttmacher Institute, barriers that remain to emergency contraception access include
availability at all pharmacy locations, cost, and awareness.40 A push in recent years to
expand access to all pharmacies has been made, leading to legislative requirements in some
states, but has been met with resistance in others due to civil liberties associated with
refusal to stock various contraceptive methods. The barrier of cost, however, remains
prevalent. Over-the-counter levonorgestrel costs between $25 and $50 on average and the
majority of insurance plans do not cover over-the-counter products without prescriptions.41
This leaves a significant gap in care to those below the poverty line who may not be able
to afford over-the-counter access, requiring them to see a provider and thus extending the
time spent without emergency contraception.
1.3.2

Benefits to Board-Authorization of a Protocol

In 2017, Kentucky legislature passed administrative regulation 201 KAR 2:380,
which expanded pharmacist scope of practice by authorizing the Board of Pharmacy to
approve a protocol allowing pharmacists to initiate the dispensing of noncontrolled
prescriptions for the treatment of certain conditions specified in the regulation.42,43
Contained within the regulation is the requirement that each participating pharmacy must
have a collaborating prescriber sign the protocol and that pharmacists complete an
educational course approved by the Board of Pharmacy.
11

A board-authorized protocol allowing pharmacists to provide emergency
contraception would effectively aid in alleviating the monetary burden associated with
OTC access by allowing for insurance/health savings account billing. Currently, 201 KAR
2:380 allows for board-authorization of protocols for 13 different conditions. Of these 13
conditions, one is for “Self-care conditions appropriately treated with over-the-counter
medications and products”; however, at the initiation of this work, no protocol for
nonprescription/over-the-counter emergency contraception had been approved. Protocol
authorization would allow pharmacists to bill insurance, particularly Kentucky Medicaid,
which covers OTC emergency contraception. Not only would this mitigate the barrier of
cost, but it would provide rapid access to those who may otherwise be forced to schedule
an appointment and see a provider prior to obtaining emergency contraception due to the
high associated cost.
In addition to mitigation of cost barriers, a recent study found that pharmacists
practicing in states that allow for pharmacist provision of emergency contraception with
completion of required continuing education have been shown to be associated with
improved patient access to oral emergency contraception as well as more accurate patient
counseling.44 Evidence provided by the growing body of literature support pharmacist
provision of OTC emergency contraception and sheds light on its patient-centered benefits.

1.4

Objectives
The objectives of this work were to: 1) understand the opinions of Kentucky

pharmacists and student pharmacists with regard to provision of hormonal contraception
services through a board-authorized protocol; 2) understand the opinions of Kentucky
12

pharmacists and student pharmacists with regard to provision of OTC emergency
contraception services through a board-authorized protocol; and 3) identify and implement
policy-based solutions to increase access to OTC emergency contraception.
CHAPTER 2. METHODS
2.1

Survey of Pharmacist Opinions
A voluntary, 20-item online questionnaire, administered via REDCap,45 was

disseminated between January and February 2020 to pharmacist members of the Kentucky
Pharmacists Association (KPhA), the Kentucky Society of Health-System Pharmacists
(KSHP), and the Advancing Pharmacy Practice in Kentucky Coalition (APPKC) via email.
In addition, members of the Kentucky Pharmacist Network Group were invited via a
private Facebook46 group post. The questionnaire was approved by the University of
Kentucky Institutional Review Board. Following the initial invitation, two reminder
invitations were sent at 1-week intervals. No incentives were offered for participation. The
questionnaire was developed following a review of current literature regarding pharmacist
opinions on provision of hormonal contraception in other states.15–17,19,20 The survey aimed
to identify Kentucky pharmacists’ opinions, self-evaluated knowledge, and comfort level
regarding the provision of prescription hormonal contraception as well as nonprescription
emergency contraception via a board-authorized protocol. In addition, the survey aimed to
gather perceived barriers and benefits associated with provision of prescription hormonal
contraception via protocol. Prior to dissemination, the questionnaire was pilot tested by a
group of pharmacists at the University of Kentucky College of Pharmacy for functionality
and face validity.
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Demographic factors collected included: age, years in practice, primary practice
setting (e.g., chain, independent), county (for classification as rural/urban), estimated daily
prescription volume, and gender. Additionally, the questionnaire collected opinions
regarding provision of OTC emergency contraception and prescription hormonal
contraception via a board-authorized protocol. Opinions collected included: 1) support for
provision of prescription hormonal contraception and nonprescription emergency
contraception; 2) benefits/barriers associated with provision of prescription hormonal
contraception; 3) intent to provide contraceptive services in their pharmacy; and 4) selfrated knowledge and comfort level in provision of contraceptive services via a boardauthorized protocol. Opinions regarding support, intent to provide, and knowledge/comfort
level were rated via a 5-point Likert scale, ranging from “strongly disagree” to “strongly
agree”. Perceived barriers and benefits were rated on a 3-point scale (“No barrier/benefit
at all”, “Slight barrier/benefit”, “Significant barrier/benefit”). Opinions were also gathered
regarding an appropriate service fee, given that, at the time of the survey, Kentucky law
did not require reimbursement for pharmacist services. Pharmacists were informed that this
hypothetical fee is for services provided only and does not include the cost of medications
or any associated dispensing fees. The full questionnaire is available in the supplementary
materials.
2.1.1

Analysis

Data were analyzed and statistical models were developed via RStudio.47 Counties
were classified as rural/urban using the Office of Management and Budget (OMB)
Metropolitan Statistical Area Designations.48 For analysis, subjects were limited to
respondents practicing in a community setting. Descriptive statistics were used to quantify
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demographic factors as well as pharmacist opinions. Additionally, scales were
dichotomized to “agree” or “disagree/neutral” and “barrier/benefit” or “no barrier/benefit”.
Chi-squared tests were used as exploratory analyses prior to multivariable analysis. A
multivariable logistic regression model was used to identify any associations between
demographic factors and odds of support for provision of prescription hormonal
contraception. Due to correlations between age and years in practice, age was excluded
from the model. All other collected demographic variables (years in practice, primary
practice setting, rural/urban practice location, estimated daily prescription volume, and
gender) were included as covariates in the final regression model. In addition, McNemar’s
test was used to identify any statistically significant differences in support for provision of
prescription hormonal contraception between dosage forms (oral, transdermal, vaginal,
injectable).

2.2

Survey of Student Pharmacist Opinions
A voluntary, 17-item online questionnaire, administered by REDCap,45 was

disseminated in September 2020 via Canvas49 to professional year one (PY1) through
professional year three (PY3) students at the University of Kentucky College of Pharmacy
through their respective Patient Care Experience (PaCE) course. The questionnaire was
likewise approved by the University of Kentucky Institutional Review Board. Two
reminder announcements were posted at 1-week intervals following the initial
announcement. As an incentive for participation, students who completed the questionnaire
received a link to enter themselves in a drawing for one of ten $10 gift cards awarded to
members of each class. The questionnaire was developed through modification of the
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pharmacist questionnaire for the student population. The survey aimed to gauge student
pharmacists’ opinions, self-evaluated knowledge, and comfort level regarding the
provision of prescription hormonal contraception as well as OTC emergency contraception
via a board-authorized protocol. In addition, the survey aimed to gather perceived barriers
and benefits associated with provision of prescription hormonal contraception via protocol.
Demographic factors collected included: professional year, age, gender, in-state/outof-state, current practice setting, years of experience, and anticipated practice site.
Additionally, the questionnaire collected opinions regarding provision of OTC emergency
contraception and prescription hormonal contraception via a board-authorized protocol.
Opinions collected included: 1) support for provision of prescription hormonal
contraception and OTC emergency contraception; 2) benefits/barriers associated with
provision of prescription hormonal contraception; 3) intent to provide contraceptive
services in their pharmacy; and 4) self-rated knowledge and comfort level in provision of
contraceptive services via a board-authorized protocol. Opinions were collected using
questions adapted from the pharmacist questionnaire and likewise used the same scales.
The full questionnaire is available in the supplementary materials.
2.2.1

Analysis

Data were analyzed via RStudio.47 Years of experience was excluded from the
dataset due to the extremely narrow range and limited responses. Descriptive statistics were
used, similarly to analysis of the pharmacist survey, to quantify demographic factors as
well as student pharmacist opinions. A multivariable logistic regression model was used to
identify any associations between demographic factors and odds of support for provision
of prescription hormonal contraception. Due to minimal variance and similarity to year in
16

program, age was excluded from the final model. Current practice site was also excluded
due to the high number of students who did not report currently practicing. All other
collected demographic variables (year in program, gender, in-state/out-of-state, and
anticipated future practice setting) were included as covariates in the model. McNemar’s
test was also used to identify and statistically significant differences in support for
provision of prescription hormonal contraception between dosage forms (oral, transdermal,
vaginal, injectable).
CHAPTER 3. SURVEY RESULTS
3.1

Survey of Pharmacist Opinion
3.1.1

Descriptive Results

Of 318 total responses, 151 were from pharmacists practicing in a communitybased setting. Due to the nature of convenience sampling and unknown overlap between
sampled groups, we were unable to calculate a response rate.
Our sample of community-based pharmacists included 41.1% male and 55.6%
female respondents (Table 3-1). Practice setting was evenly distributed, with 54.3%
reporting practicing in a chain setting and 45.7% reporting practicing in an independent
setting. Most respondents reported practicing in an urban location (60.3%). A wide range
of practice experience was reported, with the most common range being ≤10 years in
practice (39.1%).
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Table 3-1: Subject Demographics - Pharmacist Survey (n=151)
Years in Practice
≤10
11-30
>30
Missing
Gender
Male
Female
Missing
Setting
Chain
Independent
Missing
Daily Prescription Volume
<250
250-449
≥450
Missing
Practice Locationa
Urban
Rural
Missing

n (%)
59 (39.1)
46 (30.5)
39 (25.8)
7 (4.6)
62 (41.1)
84 (55.6)
5 (3.3)
82 (54.3)
69 (45.7)
0 (0.0)
61 (40.4)
53 (35.1)
34 (22.5)
3 (2.0)
91 (60.3)
55 (36.4)
5 (3.3)

Pharmacists were largely supportive of provision of prescription hormonal
contraception services (Figure 3-1). Support was highest for oral (61%) and transdermal
(54%) dosage forms. Support for injectable (38%) and vaginal dosage forms (47%) was
considerably lower.
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Figure 3-1: Support for Hormonal Contraception Provision Among Community
Pharmacists
Pharmacists reported confidence in their abilities to follow a protocol to determine
eligibility to receive therapy for oral (59.6%), transdermal (57.0%), vaginal (53.6%), and
injectable (51.0%) dosage forms of prescription hormonal contraception (Figure 3-2).
Pharmacists did, however, report a need for additional training, specifically for injectable
(68.2%) and vaginal (64.2%) dosage forms. When asked what an appropriate service fee
would be, given that insurers in Kentucky were not required to provide reimbursements to
pharmacists for services provided, the most common fee ranges reported were $20-$25
(27.8%) and greater than $25 (27.8%).
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Figure 3-2: Confidence in Abilities to Follow a Protocol to Determine Patient Eligibility
for Hormonal Contraception Among Pharmacists
Commonly perceived barriers (Figure 3-3) to implementation reported by
pharmacist respondents were reimbursement (98%), time (89%), provider resistance
(87%), training (78%), and belief in the need for pelvic exams (77%). Personal beliefs was
the least cited barrier, with only 13% of pharmacists reporting this as a barrier to
implementation.
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Figure 3-3: Perceived Barriers to Implementation of Hormonal Contraception Services
Among Pharmacists
Perceived benefits of implementation (Figure 3-4) were evenly distributed, with
new business opportunities (90%) being the most commonly cited benefit and personal
professional development (81%) being the least cited.

Figure 3-4: Perceived Benefits of Implementation of Hormonal Contraception Services
Among Pharmacists
Pharmacists were also very supportive of provision of OTC emergency
contraception via a board-authorized protocol, with 65% of pharmacists indicating support
21

(Figure 3-5). There was, however, a small subsection of pharmacists who strongly
disagreed (15%). Additionally, 57.9% of pharmacists indicated they would, given its
approval, offer this service in their pharmacy. Pharmacists again were confident in their
ability to follow a protocol to determine patient eligibility (79.8%); however, 54.9%
indicated that additional training would be necessary.

Figure 3-5: Support for Emergency Contraception Provision Among Community
Pharmacists
3.1.2

Analyses

McNemar’s test (Table 3-2) was used to identify and statistically significant
differences in support between dosage forms. Differences in support were statistically
significant between all dosage form pairs, with the exception of vaginal and transdermal,
as we found no significant differences between support levels for these two forms (p=0.08).
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Table 3-2: Differences in Pharmacist Support for Hormonal Contraception Provision by
Dosage Form (p values)
Oral
Injectable
Transdermal
Vaginal
Oral
Injectable

<0.01*

Transdermal

<0.01*

<0.01*

Vaginal

<0.01*

0.02*

0.08

*Statistically significant at a=0.05

A multivariable logistic regression model (Table 3-3) was used identify any
significant differences in odds of support across demographic factors. No demographic
factors were found to have a statistically significant impact on odds of support with the
exception of years in practice. Pharmacists in practice 11-30 years were found to be a
significantly decreased odds of support for oral (72% less likely), transdermal (62% less
likely), and vaginal (74% less likely) dosage forms compared to those in practice 10 years
or less. Additionally, pharmacists in practice greater than 30 years were found to be at
significantly lower odds (65% less likely) of support for the oral form. No statistically
significant differences in support across demographic factors were found with regard to the
injectable dosage form.
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Table 3-3: Adjusted Odds (aOR) of Pharmacist Support for Provision of Prescription
Hormonal Contraception by Dosage Form
Oral
Transdermal
Injectable
Vaginal
aOR
aOR
aOR
aOR
(95% CI)
(95% CI)
(95% CI)
(95% CI)
Years in Practice
≤10
Reference
Reference
Reference
Reference
11-30
0.28
0.38
0.55
0.26
(0.10-0.74)*
(0.15-0.95)*
(0.20-1.44)
(0.10-0.67)*
>30
0.35
0.72
1.05
0.46
(0.12-0.97)*
(0.27-1.90)
(0.39-2.80)
(0.17-1.2)
Gender
Male
Reference
Reference
Reference
Reference
Female
1.43
1.38
0.57
0.87
(0.63-3.29)
(0.63-3.07)
(0.25-1.26)
(0.39-1.93)
Setting
Chain
Reference
Reference
Reference
Reference
Independent
1.69
1.83
2.00 (
1.18
(0.66-4.42)
(0.75-4.63)
0.79-5.18)
(0.47-3.01)
Daily Prescription Volume
<250
Reference
Reference
Reference
Reference
250-449
0.59
0.84
1.57
0.62
(0.23-1.55)
(0.34-2.11)
(0.61-4.18)
(0.24-1.58)
≥450
0.82
1.04
1.42
0.81
(0.25-2.68)
(0.34-3.21)
(0.44-4.64)
(0.26-2.54)
Practice Locationa
Urban
Reference
Reference
Reference
Reference
Rural
1.74
1.16
0.96
0.63
(0.73-4.26)
(0.50-2.67)
(0.40-2.24)
(0.27-1.47)
*Statistically significant at a=0.05

3.2

Survey of Student Pharmacist Opinions
3.2.1

Descriptive Results

A total of 260 students responded to the survey (Table 3-4), resulting in a response
rate of 64.7%. Distribution was fairly even between professional years, with 32.3% of
respondents in their first year, 31.5% in their second year, and 35.4% in their third year.
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Our sample consisted of a considerably larger percentage of females (71.9%) than males
(26.9%), although this is likely reflective of class demographics. Additionally, the majority
of students in the sample were in-state (72.3%). We received a wide distribution of
responses with regard to anticipated future practice site, with hospital inpatient (43.5%)
being most common, followed by ambulatory clinic (16.9%), chain community-based
(12.7%), and independent community-based (10.8%).
Table 3-4: Subject Demographics - Student Survey (n = 260)
Professional Year
PY1
PY2
PY3
Missing
Gender
Male
Female
Missing
In-State/Out-of-State
In-State
Out-of-State
Missing
Anticipated Future Practice Setting
Chain
Independent
Hospital Outpatient
Hospital Inpatient
Ambulatory Clinic
Other
Missing

n (%)
84 (32.3)
82 (31.5)
92 (35.4)
2 (0.8)
70 (26.9)
187 (71.9)
3 (1.2)
188 (72.3)
70 (26.9)
2 (0.8)
33 (12.7)
28 (10.8)
25 (9.6)
113 (43.5)
44 (16.9)
14 (5.4)
3 (1.2)

Support among students for provision of hormonal contraception via a boardauthorized protocol was overwhelmingly high (Figure 3-6). Support was highest for oral
(91%), transdermal (82%), and vaginal (73%) forms, while support for the injectable form
was slightly lower (66%).
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Figure 3-6: Support for Hormonal Contraception Provision Among Student Pharmacists
While it should be noted that only the third-year students had completed their
education in hormonal contraception at the time of the survey, students were nevertheless
confident in their ability to follow a protocol to determine eligibility to receive therapy.
Confidence was highest for the oral form (53.1%), and was considerably lower for
transdermal (38.1%), vaginal (39.2%), and injectable (35.8%) forms (Figure 3-7). Students
did, however, note a need for additional training. 49.6% reported a need for additional
training prior to provision of the oral dosage form, 56.9% for the transdermal form, 56.2%
for the vaginal form, and 62.7% for the injectable form.

26

Figure 3-7: Confidence in Abilities to Follow a Protocol to Determine Patient Eligibility
for Hormonal Contraception Among Student Pharmacists
Commonly perceived barriers to implementation (Figure 3-8) among students were
provider resistance (83%), time (82%), and reimbursement (82%). Notably, the least
commonly cited barrier to implementation was personal beliefs, which was cited by 8% of
students.
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Figure 3-8: Perceived Barriers to Implementation of Hormonal Contraception Services
Among Student Pharmacists
Perceived benefits to implementation (Figure 3-9) among students were evenly
distributed. The most cited benefit was advancement of the profession, which was cited by
100% of students. The least cited benefit was personal professional development (96%).

Figure 3-9: Perceived Benefits to Implementation of Hormonal Contraception Services
Among Student Pharmacists
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Support was likewise high for provision of nonprescription emergency
contraception via protocol, with 88% of students indicating support (Figure 3-10).
Additionally, 79.2% of students reported confidence in their ability to follow a protocol to
determine eligibility. 63.4% of students did, however, cite a need for additional training.
Students also overwhelmingly agreed that a protocol allowing for provision of
nonprescription emergency contraception would increase availability (93.1%).

Figure 3-10: Support for Emergency Contraception Provision Among Student
Pharmacists
3.2.2

Analyses

McNemar’s Test (Table 3-5) was used to identify any statistically significant
differences in support between dosage forms. Differences in support were found to be
statistically significant for all dosage form pairs.
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Table 3-5: Differences in Student Support for Hormonal Contraception Provision by
Dosage Form (p values)
Oral
Injectable
Transdermal
Vaginal
Oral
Injectable

<0.01*

Transdermal

<0.01*

<0.01*

Vaginal

<0.01*

0.05*

<0.01*

*Statistically significant at a=0.05

A multivariable logistic regression model was used to identify any statistically
significant differences in odds of support across demographic factors (Table 3-6). Both
professional year and anticipated future practice setting were found to have a significant
impact on odds of support. PY3 students were at higher odds of support for provision of
the oral (286% higher) and vaginal (157% higher) dosage forms. No statistically significant
differences in support among professional years were found for the transdermal and
injectable forms. With regard to anticipated future practice setting, students who anticipate
practicing in a hospital inpatient setting were at 165% higher odds of support of provision
of the injectable dosage form. No other significant differences were found.
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Table 3-6: Adjusted Odds (aOR) of Student Support for Provision of Prescription
Hormonal Contraception by Dosage Form
Oral
Transdermal
Injectable
Vaginal
aOR
aOR
aOR
aOR
(95% CI)
(95% CI)
(95% CI)
(95% CI)
Professional Year
PY1
Reference
Reference
Reference
Reference
PY2
1.35
1.90
1.47
2.12
(0.47-4.09)
(0.78-4.83)
(0.68-3.24)
(0.98-4.75)
PY3
3.86
1.69
1.06
2.57
(1.05-18.60)*
(0.71-4.10)
(0.50-2.23)
(1.18-5.75)*
Gender
Male
Reference
Reference
Reference
Reference
Female
0.53
0.68
1.75
1.69
(0.11-1.80)
(0.26-1.61)
(0.89-3.46)
(0.82-3.49)
In-State/Out-of-State
In-State
Reference
Reference
Reference
Reference
Out-of-State
1.01
0.66
0.52
0.94
(0.31-3.89)
(0.28-1.59)
(0.25-1.06)
(0.44-2.07)
Anticipated Future Practice Setting
Chain
Reference
Reference
Reference
Reference
Independent
0.51
1.41
1.80
1.47
(0.06-2.98)
(0.33-3.97)
(0.59-5.62)
(0.42-5.35)
Hospital
0.36
1.08
1.64
0.72
Outpatient
(0.05-2.16)
(0.30-3.96)
(0.52-5.37)
(0.21-2.47)
Hospital
1.00
2.51
2.65
1.00
Inpatient
(0.14-4.69)
(0.86-7.08)
(1.08-6.56)*
(0.37-2.57)
Ambulatory
0.88
2.60
1.28
0.86
Clinic
(0.11-5.84)
(0.75-9.80)
(0.48-3.46)
(0.28-2.56)
*Statistically significant at a=0.05

CHAPTER 4. POLICY DEVELOPMENT AND IMPLEMENTATION
Following assessment of pharmacist support for provision of nonprescription
emergency contraception via a board-authorized protocol, a protocol was developed
utilizing the American College of Obstetricians and Gynecologists’ Emergency
Contraception Guidelines.50 The protocol was reviewed by pharmacists employed by the
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University of Kentucky College of Pharmacy. Upon revision, the final version of the
protocol was presented to the Kentucky Board of Pharmacy for approval.
Following presentation to the Kentucky Board of Pharmacy, the protocol, titled SelfCare Conditions Protocol: Emergency Contraception, was approved on September 30th,
2020.51 A CE course is currently in development in collaboration with APPKC.
Additionally, a social media campaign and pharmacy directory are planned in partnership
with All Access Eastern Kentucky, pending development of the CE course52. Protocol and
CE course slides are provided in the supplementary materials.
CHAPTER 5. DISCUSSION
Prior to this study, the opinions of pharmacists and student pharmacists in Kentucky
had not been assessed. The results of this study with regard to pharmacist and student
support are consistent with those seen in other areas across the country,15–17,21 thus adding
evidence to the feasibility of expansion of pharmacist services in Kentucky. While barriers
such as time and provider resistance remain concerns, progress has been seen in the areas
of training and reimbursement. As previously mentioned, virtual training programs are
available nationwide through organizations such as NCPA.29 Additionally, following the
study period in 2021, Kentucky House Bill 48 (HB 48) was signed into law, requiring
commercial insurance companies to provide reimbursement for services provided within
the scope of the practice of pharmacy.53 Notably, in the pharmacist survey, there was
consistency seen in the number of pharmacists that strongly disagreed with each dosage
form. This number was consistently smaller in the student survey and likely represents the
impact of the significant barriers such as lack of training on support levels. Student
pharmacists generally receive a level of training with regard to hormonal contraception that
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was not provided to pharmacists in the past. This idea is reinforced by the large number of
pharmacists indicating a need for additional training. Further creation of pharmacist
training programs regarding provision of hormonal contraception services, could greatly
impact support and minimize the perceived barrier of training.
In both the pharmacist and student pharmacist surveys, support for provision of
hormonal contraception was higher for oral and transdermal dosage forms and lower for
injectable and vaginal forms. A possible explanation for the lack of support for the
injectable form is safety concerns regarding long-term adverse events. The FDA requires
a black-box warning on all injectable medroxyprogesterone products regarding their
potential for bone mineral density loss and a recommendation of no more than a maximum
2 years therapy unless all other contraception options are inappropriate.54 The American
College of Obstetricians and Gynecologists, however, disagrees, stating that evidence
shows bone mineral density recovers after discontinuation and that bone mineral density
concerns

should

not

prevent

practitioners

from

prescribing

injectable

medroxyprogesterone beyond 2 years.55 While the vaginal dosage form lacks these
particular safety concerns, lack of support may be due to discomfort in counseling or other
unidentified reasons.
In comparing the results of the student survey with those of the pharmacist survey,
students were found to be generally more supportive of provision of all hormonal
contraception dosage forms. This suggests a continuation of the trend of increasing support
among newer practitioners and highlights the evolving views within the profession
regarding both hormonal contraception and expansion of pharmacist services. This trend
should be further evaluated by future studies. Additionally, while there was a subset of
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pharmacists who strongly disagreed with provision of emergency contraception via a
board-authorized protocol, this subset was considerably smaller in the students surveyed.
This subset is likely attributable to pharmacists with concerns related to personal beliefs,
given the struggle over the years to make emergency contraception available in all
pharmacies and pushes for conscience clause laws.40 This, again, sheds light on the
evolving views regarding contraception.
As previously mentioned, studies have shown the costs associated with unintended
pregnancy in Kentucky have exceeded $248.3 million.3 Policies increasing access to both
prescription hormonal contraception methods as well as emergency contraception may aid
in mitigating unintended pregnancy as well as associated costs. The Self-Care Conditions
Protocol: Emergency Contraception, provides the framework and ability for pharmacies
to offer cost-effective access to emergency contraception. Additionally, the support shown
by both pharmacists and students in the state of Kentucky sets the groundwork for
exploration into policy expansion regarding provision of hormonal contraception.
Comparability of support and confidence levels shown by Kentucky pharmacists and
students to those in other states provides evidence that Kentucky pharmacists, like their
counterparts in states that currently allow for pharmacist provision of hormonal
contraception, possess the desire and abilities to provide these services. Future directions
include legislative and policy efforts aimed at adding provision of hormonal contraception
to the 13 authorized conditions to which the Board of Pharmacy can approve a protocol for
as well as development of the protocol itself.
CHAPTER 6. LIMITATIONS
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This study was not, however, without several limitations. Limited sample size is be a
concern for both the student and the pharmacist surveys, increasing the possibility of type
II error. While many demographic factors were found to have no significant impact on odds
of support, this may be due primary to sample size and not true effect. Additionally, due to
the convenience sampling method used, the opinions expressed by surveyed pharmacists
in their respective groups may not be representative of the entire profession.
CHAPTER 7. CONCLUSIONS AND IMPLICATIONS
Both Kentucky pharmacists and student pharmacists are largely supportive of
provision of hormonal contraception, with support being highest for oral and transdermal
dosage forms. While barriers such as training and reimbursement have been addressed,
time and provider resistance remain and need to be addressed prior to effective expansion
of pharmacist provision of hormonal contraception services. Additionally, decreased odds
of support for pharmacists in practice 11-30 years vs. newer practitioners as well as the
higher support levels among students suggest a trend of increasing support among younger
pharmacy professionals. Likewise, both Kentucky pharmacists and student pharmacists are
overwhelmingly supportive of provision of nonprescription emergency contraception via
protocol and a newly approved board-authorized protocol allowing for pharmacist
provision of emergency contraception may act to increase access as well as improve patient
counseling. Together, a board-authorized protocol for emergency contraception provision
as well as one for hormonal contraception provision would allow pharmacists to serve as
an access point to women seeking contraception care. This would aid in mitigating barriers
to access and could thus lead to decreases in unintended pregnancy across the
Commonwealth.
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